Nisa Investment Advisors
STRO icon

Nisa Investment Advisors’s Sutro Biopharma STRO Stock Holding History

Nisa Investment Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46K Hold
44
– – ﹤0.01% 2802
2026
Q1 		$1.1K Hold
44
– – ﹤0.01% 2732
2025
Q4 		$509 Hold
44
– – ﹤0.01% 2813
2025
Q3 		$382 Sell
44
-82
-65% -$698 ﹤0.01% 2887
2025
Q2 		$899 Buy
+126
New +$1.03K ﹤0.01% 2757
2025
Q1 		– Sell
-6
Closed -$107 – 3054
2024
Q4 		$107 Sell
6
-890
-99% -$27.2K ﹤0.01% 2978
2024
Q3 		$31K Buy
896
+5
+0.6% +$196 ﹤0.01% 1770
2024
Q2 		$26.1K Buy
891
+11
+1% +$435 ﹤0.01% 1853
2024
Q1 		$49.7K Sell
880
-2
-0.2% -$88 ﹤0.01% 1656
2023
Q4 		$37.8K Buy
882
+876
+14,600% +$27.8K ﹤0.01% 1701
2023
Q3 		$215 Sell
6
-398
-99% -$17.3K ﹤0.01% 2654
2023
Q2 		$18.8K Buy
404
+400
+10,000% +$19.9K ﹤0.01% 2124
2023
Q1 		$0 Sell
4
-4
-50% -$254 ﹤0.01% 2695
2022
Q4 		$1K Buy
+8
New +$556 ﹤0.01% 2507
2022
Q2 		– Sell
-2,680
Closed -$220K – 2503
2022
Q1 		$220K Buy
+2,680
New +$255K ﹤0.01% 1345

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Nisa Investment Advisors's STRO Position: Q2 2026 in Review

Nisa Investment Advisors held its Sutro Biopharma (STRO) position steady in Q2 2026 at 44 shares worth $1.46K. The position accounts for ﹤0.01% of the portfolio, ranked #2802.

Nisa Investment Advisors first reported a position in STRO in Q1 2022 and has held it in 15 quarters since. The position peaked at $220K in Q1 2022. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Nisa Investment Advisors held 44 shares of Sutro Biopharma worth $1.46K as of Q2 2026.
  • Nisa Investment Advisors left its Sutro Biopharma share count unchanged in Q2 2026.
  • Sutro Biopharma made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2802 holding.
  • Nisa Investment Advisors first reported a position in Sutro Biopharma in Q1 2022 and has held it in 15 quarters since.
  • Nisa Investment Advisors's Sutro Biopharma position peaked at $220K in Q1 2022.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.